title: The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.
abstract: OBJECTIVE
  Microtubules play a critical role in many cellular functions, including cell division and mitosis. ABT-751 is a novel sulfonamide antimitotic that binds to the colchicine site on beta-tubulin that leads to a block in the cell cycle at the G2M phase, resulting in cellular apoptosis. ABT-751 was investigated in this phase 1 trial designed to assess its maximum tolerated dose (MTD), dose-limiting toxicity (DLT), tolerability, and pharmacokinetics.
  
  
  METHODS
  ABT-751 was administered on a daily (q.d.) or twice daily (b.i.d.) oral schedule for 7 days every 3 weeks to 39 patients with refractory solid tumors. Toxicity was monitored weekly. Plasma and urine ABT-751 and metabolite pharmacokinetics were determined.
  
  
  RESULTS
  The MTD for the q.d. schedule was 250 mg/d. DLTs during cycle 1 were abdominal pain, constipation, and fatigue. The MTD on the b.i.d. schedule was 150 mg. Cycle 1 of therapy with the 175 mg b.i.d. schedule was tolerated without DLT. However, six of seven patients reported grade 3 toxicity (ileus, constipation, abdominal pain, or fatigue), which occurred in cycle 2 or 3. ABT-751 was absorbed after oral administration with an overall mean T(max) of about 2 hours. The pharmacokinetics of ABT-751 were dose-proportional and time-independent. There was minimal accumulation of ABT-751 after multiple q.d. and b.i.d. doses. Efficacious concentrations, as determined from preclinical models (0.5-1.5 microg/mL), were achieved in all subjects. ABT-751 metabolism occurred primarily by glucuronidation and sulfation. No complete or partial tumor responses were noted, but one patient had a minor response, and four patients had stable disease lasting at least 6 months.
  
  
  CONCLUSIONS
  The MTD and recommended phase 2 doses for ABT-751 were 250 mg q.d. and 150 mg b.i.d. on a 7-day schedule given every 3 weeks, due to subsequent cycle toxicities at 175 mg b.i.d. dosing. Toxicities were abdominal pain, constipation, and neuropathy.
authors: Vanderbilt/Ingram Cancer Center, Nashville, Tennessee, USA. kenneth.r.hande@vanderbilt.edu
authors: Kenneth R
authors: KR
authors: Hande
authors: Anne
authors: A
authors: Hagey
authors: Jordan
authors: J
authors: Berlin
authors: Yingna
authors: Y
authors: Cai
authors: Kysa
authors: K
authors: Meek
authors: Hiro
authors: H
authors: Kobayashi
authors: A Craig
authors: AC
authors: Lockhart
authors: Diane
authors: D
authors: Medina
authors: Jeffrey
authors: J
authors: Sosman
authors: Gary B
authors: GB
authors: Gordon
authors: Mace L
authors: ML
authors: Rothenberg